NCT00400179已完成3 期
An Open-Label Multicenter, Randomized, Phase 3 Study of S-1 in Combination With Cisplatin Against 5-Fu in Combination W/ Cisplatin in Patients W/ Advanced Gastric Cancer Previously Untreated W/ Chemotherapy for Advanced Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,053
- 试验地点
- 33
- 主要终点
- Median Survival
研究概览
简要总结
This is an open-label, international, two-arm, parallel, randomized, Phase 3 study evaluating the efficacy and safety of S-1/cisplatin versus 5-FU/cisplatin in patients with advanced gastric cancer previously untreated with chemotherapy for advanced disease. Patients will be randomly assigned (1:1) to S-1/cisplatin (experimental arm) or 5-FU/cisplatin (control arm). Patients will be stratified by number of metastatic sites (one vs. more than one), locally advanced or metastatic disease, prior adjuvant therapy (yes or no), measurable or non-measurable disease, and center.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A patient must meet all of the following inclusion criteria to be eligible for enrollment in this study:
- •Has given written informed consent
- •Has histologically confirmed, unresectable, locally advanced (Stage IV) or metastatic gastric cancer, including adenocarcinoma of the gastro-esophageal junction
- •Has measurable or evaluable but non-measurable disease, defined as follows:
- •Measurable Disease - Patients with measurable disease as defined by RECIST criteria, i.e., the presence of at least one measurable lesion. A measurable lesion is one that can be accurately measured in at least one dimension with the longest diameter >_ 20 mm using conventional techniques or >_ 10 mm using spiral Computed Tomography (CT)scan. Locally recurrent disease (other than primary) is accepted if there is at least one measurable lesion (i.e. peritoneal mass, lymph node, etc.)
- •Evaluable but Non-measurable Disease - Patients with all lesions below the limits defined above for measureable disease (i.e., longest diameter < 20 mm with conventional techniques or < 10 mm with spiral CT) excluding those patients with only a primary lesion and/or with only non-evaluable cancer such as bone metastases, ascites, pleural or pericardia effusions, lymphangitic carcinomatosis of the skin or lung, previously irradiated lesions not in progression, or peritoneal carcinomatosis < 10 mm in diameter with conventional imaging techniques.
- •No prior palliative chemotherapy is permitted. Adjuvant and /or neo-adjuvant chemotherapy is permitted if more than 12 months have elapsed between the end of adjuvant or neo-adjuvant therapy and first recurrence. This does not qualify as 1st line therapy.
- •Is able to take medications orally
- •Is >_ 18 years of age
- •Is at least 3 weeks from prior major surgery
- •Is at least 4 weeks from prior radiotherapy
- •Has a ECOG performance status 0 to 1
- •Has adequate organ function as defined by the following criteria:
- •AST (SGOT) and ALT (SGPT) <_ 2.5 x ULN; if liver function abnormalities are due to underlying liver metastasis, AST (SGOT) and ALT (SGPT) <_ 5 x ULN
- •Total serum bilirubin of <_ 1.5 x ULN
- •Absolute granulocyte count of >_ 1,500/mm (i.e. >_ 1.5 x 10/L by International Units (IU)
- •Platelet count >_ 100,000/mm (IU: >_ 100 x 10/L
- •Hemoglobin value of >_ 9.0 g/dL
- •Calculated creatinine clearance >_ 60 mL/min (Cockcroft-Gault formula)
- •Is willing and able to comply with scheduled visits, treatment plans, laboratory tests and other study procedures
排除标准
- •Exclude a patient from this study if he/she does not fulfill the inclusion criteria, or if any of the following conditions are observed:
- •Has had a treatment with any of the following within the specified timeframe prior to study drug administration:
- •Any prior palliative chemotherapy or any previous therapy for malignancy, including any chemotherapy, immunotherapy, biologic or hormonal therapy, within the past 5 years.
- •Adjuvant or neo-adjuvant therapy within the past 12 months
- •Concurrent treatment with any investigational anti-cancer agent
- •Prior cisplatin as neo-adjuvant and /or adjuvant chemotherapy with cumulative dose > 300 mg/m
- •> 25% of marrow-bearing bone radiated
- •Concurrent treatment with an investigational agent or within 30 days from randomization
- •Concurrent enrollment in another clinical study
- •Has a serious illness or medical condition(s) including, but not limited to the following:
- •Known brain or leptomeningeal metastases
- •Uncontrolled ascites requiring drainage at least twice a week
- •Other malignancies within the past 5 years, except adequately treated carcinoma-in-situ of the cervix or non-melanoma skin cancer
- •Myocardial infarction within the last 6 months, severe/unstable angina, congestive heart failure New York Heart Association (NYHA) class III or IV
- •Chronic nausea, vomiting or diarrhea
- •Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS-related illness
- •Psychiatric disorder that may interfere with consent and/or protocol compliance
- •Known neuropathy, Grade 2 or higher
- •Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgement of the Investigator would make the patient inappropriate for entry into this study
- •Is receiving concomitant treatment with drugs interacting with S-
- •The following drugs are prohibited because there may be an interaction with S-1:
- •Sorivudine, uracil, cimetidine, folinic acid, and dipyridamole (may enhance S-1 activity)
- •Allopurinol (may diminish S-1 activity
- •Phenytoin (S-1 may enhance phenytoin activity)
- •Flucytosine, a fluorinated pyrimidine antifungal agent (may enhance S-1 activity)
- •Is receiving concomitant treatment with drugs interacting with 5-FU:
- •Sorivudine, uracil, cimetidine, folinic acid, and dipyridamole(may enhance 5-FU activity)
- •Allopurinol (may diminish 5-FU activity)
- •Phenytoin (5-FU may enhance phenytoin activity)
- •Is receiving concomitant treatment with drugs interacting with cisplatin:
- •Phenytoin (cisplatin may diminish phenytoin activity)
- •Aminoglycosides (should be avoided within 8 days after cisplatin administration)
- •Ethyol (may diminish cisplatin activity
- •Is a pregnant or lactating female
- •Has known hypersensitivity to 5-FU or cisplatin
- •Patients with reproductive potential who refuse to use an adequate means of contraception (including male patients)
研究组 & 干预措施
A
Active Comparator
In Arm A, S-1 25 mg/m² was administered orally BID from Day 1 through Day 21 followed by a recovery period from Days 22 through Day 28. On Day 1, the morning dose of S-1 was administered before cisplatin 75 mg/m2 administration as a 1- to 3-hour IV infusion. This regimen was repeated every 4 weeks. S-1 was administered one hour before or one hour after a meal with a glass of water (approximately 100 mL).
干预措施: S-1/Cisplatin (Drug)
B
Active Comparator
In Arm B, 5-FU 1000 mg/m2/24 hours was administered by continuous intravenous infusion (CIV) over 120 hours (on Days 1 through 5). This regimen was repeated every 4 weeks. 5-FU CIV followed cisplatin infusion on Day 1. All 5-FU used in this study was commercially available product.
干预措施: 5-FU/cisplatin (Drug)
结局指标
主要结局
Median Survival
时间窗: The cutoff date for survival analysis was 07 March 2008 (12 months after last patient randomized).
Survival was defined as the time from the date of randomization to the time of death (from any cause) for each patient.
次要结局
- Duration of Response (DR)(Data cutoff was 07 March 2008 (12 months after last patient was randomized).)
- Overall Response Rate (ORR)(Data cutoff was 07 March 2008 (12 months after last patient randomized).)
- Progression-free Survival (PFS)(From date of randomization until date of first documented PD, date of death, or until data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.)
- Time to Treatment Failure (TTF)(From date of randomization until date of permanent discontinuation of S-1 or 5-FU, first documented PD, death, or data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.)
研究者
研究点 (33)
Loading locations...
相似试验
已完成
3 期
An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 MutationLeukemia, MyeloidIsocitrate DehydrogenaseNCT02577406Celgene319
终止
3 期
A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLCAdvanced NSCLCNCT05106335Jiangsu HengRui Medicine Co., Ltd.1
进行中（未招募）
3 期
Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)Chronic Myeloid Leukemia, Chronic PhaseNCT03722420Il-Yang Pharm. Co., Ltd.238
已完成
3 期
Study of S-1, S-1/CDDP, and 5-FU/CDDP for Advanced Gastric CancerGastric CancerNCT00202969Taiho Pharmaceutical Co., Ltd.180
进行中（未招募）
3 期
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Early Breast CancerNCT04961996Hoffmann-La Roche4,170